-

Tempus to Participate in the Piper Sandler 37th Annual Healthcare Conference

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that it will participate in the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3rd in New York City. Jim Rogers, Chief Financial Officer at Tempus, will participate in a fireside chat at 10:30 AM ET.

The live webcast will be available through the events page of Tempus’ Investor Relations website or by clicking the following link: https://event.webcasts.com/starthere.jsp?ei=1743260&tp_key=c0dedf6883.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Contacts

Tempus Communications
Erin Carron
Erin.carron@tempus.com

Tempus Investor Relations
Elizabeth Krutoholow
investorrelations@tempus.com

Industry:

Tempus AI, Inc.

NASDAQ:TEM
Release Versions
English

Contacts

Tempus Communications
Erin Carron
Erin.carron@tempus.com

Tempus Investor Relations
Elizabeth Krutoholow
investorrelations@tempus.com

More News From Tempus AI, Inc.

Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced that 13 abstracts have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27 in Madrid. At this year’s congress, Tempus will showcase clinical research revealing insights in cancer biology, treatment response and patient outcomes across solid tumors, including prostate, breast, non-small cell lung cancer (NSCLC), renal cell carcinoma and gynecologic mali...

Tempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral Regurgitation

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Tempus ECG-MR, an AI product that analyzes standard 12-lead resting electrocardiograms (ECGs) to detect signs associated with undiagnosed moderate or severe mitral regurgitation (MR). MR is a common form of heart valve disease where blood leaks backward through the mitral valve. Because early stages are often asymptomatic or manifest as no...

Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s RNA Foundation Model

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX). Additionally, the two companies have entered into a new agreement under which Tempus will license Recursion’s RNA Foundation Model. Tempus and Recursion have extended their multi-year data partnership through November 2029. The companies share a mission to use foundation models to advance precision medicine, and entered into a co...
Back to Newsroom